CFI-400945 inhibits the proliferation of cancer cells with highly expressed PLK4; suppresses liver cancer progression through cell cycle inhibition and induces antitumor immunity; centrinone B treatment decreases the viability of different hepatocellular carcinoma cell lines. Here, PLK4 is linked to hepatocellular carcinoma.